An assessment by the Statin cognitive safety task force: 2014 update

Journal of Clinical Lipidology

Volumn 8, Issue 3 SUPPL, 2014, Pages

  Rojas Fernandez, Carlos H ^a,b   Goldstein, Larry B ^c   Levey, Allan I ^d   Taylor, Beth A ^e   Bittner, Vera ^f  

^a UNIVERSITY OF WATERLOO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c DURHAM VA MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF HARTFORD   (United States)

^f University of Alabama at Birmingham   (United States)

Author keywords

Adverse drug effects; Cognition; Iatrogenesis; Memory; Statins

Indexed keywords

AMITRIPTYLINE; ANTIPARKINSON AGENT; BENZATROPINE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DARIFENACIN; DIAZEPAM; DIMENHYDRINATE; DIPHENHYDRAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYZINE; IMIPRAMINE; LORAZEPAM; MEVINOLIN; MIRTAZAPINE; MORPHINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OPIATE; OXYBUTYNIN; PAROXETINE; PRAVASTATIN; PROMETHAZINE; SIMVASTATIN; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL; UNINDEXED DRUG;

AGING; ALZHEIMER DISEASE; ARTICLE; CLINICAL DECISION MAKING; COGNITION; COGNITIVE DEFECT; CONSENSUS DEVELOPMENT; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG SAFETY; EVIDENCE BASED MEDICINE; FRONTOTEMPORAL DEMENTIA; GENERAL PRACTITIONER; HUMAN; HYPERLIPIDEMIA; MEMORY; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; NEUROLOGIST; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SCREENING; SYSTEMATIC REVIEW (TOPIC); CARDIOVASCULAR DISEASES; COGNITION DISORDERS; DRUG COMBINATION; RISK;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASES; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MILD COGNITIVE IMPAIRMENT; ODDS RATIO;

EID: 84899874858     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.02.013     Document Type: Article

References (84)

1. N.J. Stone, J. Robinson, and A.H. Lichtenstein et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [e-pub ahead of print] Circulation 2013 10.1016/j.jacc.2013.11.002 Accessed March 14, 2014
2. G.H. Guyatt, A.D. Oxman, and G.E. Vist et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926
3. P.A. James, S. Oparil, and B.L. Carter et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) JAMA 311 5 2014 507 520
4. C.H. Rojas-Fernandez, and J.C. Cameron Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations Ann Pharmacother 46 2012 549 557
5. K.P. Padala, P.R. Padala, D.P. McNeilly, J.A. Geske, D.H. Sullivan, and J.F. Potter The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer's dementia: a prospective withdrawal and rechallenge pilot study Am J Geriatr Pharmacother 10 2012 296 302
6. U.S. Food and Drug Administration. FDA Drug Safety Communication: important safety label changes to cholesterol-lowering statin drugs. Available at: http://www.fda.gov/drugs/drugsafety/ucm293101.htm. Accessed November 6, 2013.
7. R.C. Petersen Clinical practice. Mild cognitive impairment N Engl J Med 364 2011 2227 2234
8. H. Feldman, A.R. Levy, and G.Y. Hsiung et al. A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results Neuroepidemiology 22 2003 265 274
9. V. Hachinski, C. Iadecola, and R.C. Petersen et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards Stroke 37 2006 2220 2241
10. P. Robert, S. Ferris, S. Gauthier, R. Ihl, B. Winblad, and F. Tennigkeit Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice? Alzheimers Res Ther 2 2010 24
11. Z.S. Nasreddine, N.A. Phillips, and V. Bedirian et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment J Am Geriatr Soc 53 2005 695 699
12. D.J. Gill, A. Freshman, J.A. Blender, and B. Ravina The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease Mov Disord 23 2008 1043 1046
13. S. Hoops, S. Nazem, and A.D. Siderowf et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease Neurology 73 2009 1738 1745
14. A. Gottschalk, and S.A. Flocke Time spent in face-to-face patient care and work outside the examination room Ann Fam Med 3 2005 488 493
15. E. Hing, D.K. Cherry, and D.A. Woodwell National Ambulatory Medical Care Survey: 2004 summary Adv Data 2006 1 33
16. N.K. Steenland, C.M. Auman, and P.M. Patel et al. Development of a rapid screening instrument for mild cognitive impairment and undiagnosed dementia J Alzheimers Dis 15 2008 419 427
17. J.S. Lin, E. O'Connor, R.C. Rossom, L.A. Perdue, and E. Eckstrom Screening for cognitive impairment in older adults: a systematic review for the U.S. Preventive Services Task Force Ann Intern Med 159 2013 601 612
18. C.B. Cordell, S. Borson, M. Boustani Medicare Detection of Cognitive Impairment Workgroup Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting Alzheimers Dement 9 2013 141 150
19. Alzheimer's Association. 2013 Alzheimer's disease facts and figures. http://www.alz.org/downloads/facts-figures-2013.pdf. December 29, 2013.
20. C.I. Neutel, H. Morrison, N.R. Campbell, and M. de Groh Statin use in Canadians: trends, determinants and persistence Can J Public Health 98 2007 412 416
21. Centers for Disease Control and Prevention. National Center for Health Statistics. Health, United States, 2010: with special feature on death and dying. Available at: http://www.cdc.gov/nchs/data/hus/hus10.pdf. Accessed February 5, 2014.
22. L.G. Brooks, and D.A. Loewenstein Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions Alzheimers Res Ther 2 2010 28
23. J.J. Manly, M.X. Tang, N. Schupf, Y. Stern, J.P. Vonsattel, and R. Mayeux Frequency and course of mild cognitive impairment in a multiethnic community Ann Neurol 63 2008 494 506
24. R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, and E. Kokmen Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 1999 303 308
25. K. Ritchie, S. Artero, and J. Touchon Classification criteria for mild cognitive impairment: a population-based validation study Neurology 56 2001 37 42
26. S.M. Landau, D. Harvey, and C.M. Madison et al. Alzheimer's Disease Neuroimaging I. Comparing predictors of conversion and decline in mild cognitive impairment Neurology 75 2010 230 238
27. S. Iliffe, and L. Pealing Subjective memory problems BMJ 340 2010 c1425
28. B. Reisberg, M.B. Shulman, C. Torossian, L. Leng, and W. Zhu Outcome over seven years of healthy adults with and without subjective cognitive impairment Alzheimers Dement 6 2010 11 24
29. F. Jessen, B. Wiese, C. Bachmann German Study on Aging, Cognition and Dementia in Primary Care Patients Study Group Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment Arch Gen Psychiatry 67 2010 414 422
30. L.M. Brass, M.J. Alberts, L. Sparks National Lipid Association Statin Safety Task Force Neurology Expert Panel An assessment of statin safety by neurologists Am J Cardiol 97 2006 86C 88C
31. L. Galatti, G. Polimeni, F. Salvo, M. Romani, A. Sessa, and E. Spina Short-term memory loss associated with rosuvastatin Pharmacotherapy 26 2006 1190 1192
32. A. Orsi, O. Sherman, and Z. Woldeselassie Simvastatin-associated memory loss Pharmacotherapy 21 2001 767 769
33. K.P. Padala, P.R. Padala, and J.F. Potter Simvastatin-induced decline in cognition Ann Pharmacother 40 2006 1880 1883
34. G.P. Parale, N.N. Baheti, P.M. Kulkarni, and N.V. Panchal Effects of atorvastatin on higher functions Eur J Clin Pharmacol 62 2006 259 265
35. J.T. Peters, C.L. Garwood, and M. Lepczyk Behavioral changes with paranoia in an elderly woman taking atorvastatin Am J Geriatr Pharmacother 6 2008 28 32
36. L.R. Wagstaff, M.W. Mitton, B.M. Arvik, and P.M. Doraiswamy Statin-associated memory loss: analysis of 60 case reports and review of the literature Pharmacotherapy 23 2003 871 880
37. M.A. Evans, and B.A. Golomb Statin-associated adverse cognitive effects: survey results from 171 patients Pharmacotherapy 29 2009 800 811
38. M.F. Muldoon, S.D. Barger, and C.M. Ryan et al. Effects of lovastatin on cognitive function and psychological well-being Am J Med 108 2000 538 546
39. M.F. Muldoon, C.M. Ryan, S.M. Sereika, J.D. Flory, and S.B. Manuck Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults Am J Med 117 2004 823 829
40. I. Hajjar, J. Schumpert, V. Hirth, D. Wieland, and G.P. Eleazer The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment J Gerontol A Biol Sci Med Sci 57 2002 M414 M418
41. H. Jick, G.L. Zornberg, S.S. Jick, S. Seshadri, and D.A. Drachman Statins and the risk of dementia Lancet 356 2000 1627 1631
42. K. Rockwood, S. Kirkland, and D.B. Hogan et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people Arch Neurol 59 2002 223 227
43. K. Steenland, L. Zhao, F.C. Goldstein, and A.I. Levey Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment J Am Geriatr Soc 61 2013 1449 1455
44. J.V. Agostini, M.E. Tinetti, L. Han, G. McAvay, J.M. Foody, and J. Concato Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults J Am Geriatr Soc 55 2007 420 425
45. K. Yaffe, E. Barrett-Connor, F. Lin, and D. Grady Serum lipoprotein levels, statin use, and cognitive function in older women Arch Neurol 59 2002 378 384
46. J.M. Starr, B. McGurn, M. Whiteman, A. Pattie, L.J. Whalley, and I.J. Deary Life long changes in cognitive ability are associated with prescribed medications in old age Int J Geriatr Psychiatry 19 2004 327 332
47. J. Benito-Leon, E.D. Louis, S. Vega, and F. Bermejo-Pareja Statins and cognitive functioning in the elderly: a population-based study J Alzheimers Dis 21 2010 95 102
48. J.W. Jukema, C.P. Cannon, A.J. de Craen, R.G. Westendorp, and S. Trompet The controversies of statin therapy: weighing the evidence J Am Coll Cardiol 60 2012 875 881
49. K.J. Swiger, R.J. Manalac, R.S. Blumenthal, M.J. Blaha, and S.S. Martin Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects Mayo Clin Proc 88 2013 1213 1221
50. K. Richardson, M. Schoen, and B. French et al. Statins and cognitive function: a systematic review Ann Intern Med 159 2013 688 697
51. B.D.L. Ott, B. Springate, K. Bixby, M. Murali, I. Dahabreh, and T. Trikalinos Do statin drugs impair cognition? A systematic review and meta-analysis Alzheimers Dement 9 2013 P666
52. R.W. Harrison, and C.H. Ashton Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers Br J Clin Pharmacol 37 1994 231 236
53. J.B. Kostis, R.C. Rosen, and A.C. Wilson Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia J Clin Pharmacol 34 1994 989 996
54. N. Cutler, J. Sramek, A. Veroff, G. Block, L. Stauffer, and C. Lines Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia Br J Clin Pharmacol 39 1995 333 336
55. F. Gengo, D. Cwudzinski, P. Kinkel, G. Block, L. Stauffer, and C. Lines Effects of treatment with lovastatin and pravastatin on daytime cognitive performance Clin Cardiol 18 1995 209 214
56. N.C. Santanello, B.L. Barber, and W.B. Applegate et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study J Am Geriatr Soc 45 1997 8 14
57. M.G. Gibellato, J.L. Moore, K. Selby, and E.A. Bower Effects of lovastatin and pravastatin on cognitive function in military aircrew Aviat Space Environ Med 72 2001 805 812
58. B.A. Golomb, DJ, H.L. White, and M.H. Criqui Do low dose statins affect cognition? Results of the UCSD Statin Study Circulation 114 2006 II 289
59. M.J. Summers, K.R. Oliver, J.S. Coombes, and R.G. Fassett Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial Pharmacotherapy 27 2007 183 190
60. I. Berk-Planken, I. de Konig, R. Stolk, H. Jansen, and N. Hoogerbrugge Atorvastatin, diabetic dyslipidemia, and cognitive functioning Diabetes Care 25 2002 1250 1251
61. J. Shepherd, G.J. Blauw, M.B. Murphy PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
62. R. Collins, J. Armitage, S. Parish, P. Sleight, R. Peto Heart Protection Study Collaborative Group Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions Lancet 363 2004 757 767
63. D.S. King, A.J. Wilburn, M.R. Wofford, T.K. Harrell, B.J. Lindley, and D.W. Jones Cognitive impairment associated with atorvastatin and simvastatin Pharmacotherapy 23 2003 1663 1667
64. D.A. Redelmeier, D. Thiruchelvam, and N. Daneman Delirium after elective surgery among elderly patients taking statins CMAJ 179 2008 645 652
65. E.R. Marcantonio Statins and postoperative delirium CMAJ 179 2008 627 628
66. S.P. Glasser, V. Wadley, and S. Judd et al. The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study Clin Cardiol 33 2010 280 288
67. G. Saher, and M. Simons Cholesterol and myelin biogenesis Subcell Biochem 51 2010 489 508
68. B. McGuinness, J. O'Hare, D. Craig, R. Bullock, R. Malouf, and P. Passmore Cochrane review on 'Statins for the treatment of dementia' Int J Geriatr Psychiatry 28 2013 119 126
69. V.E. Miron, S.P. Zehntner, and T. Kuhlmann et al. Statin therapy inhibits remyelination in the central nervous system Am J Pathol 174 2009 1880 1890
70. S. Klopfleisch, D. Merkler, and M. Schmitz et al. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo J Neurosci 28 2008 13609 13614
71. C. Tannenbaum, A. Paquette, S. Hilmer, J. Holroyd-Leduc, and R. Carnahan A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs Drugs Aging 29 2012 639 658
72. A.C. Flint, H. Kamel, and B.B. Navi et al. Inpatient statin use predicts improved ischemic stroke discharge disposition Neurology 78 2012 1678 1683
73. A.C. Flint, H. Kamel, and B.B. Navi et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival Stroke 43 2012 147 154
74. M. Blanco, F. Nombela, and M. Castellanos et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study Neurology 69 2007 904 910
75. W.G. Wood, G.P. Eckert, U. Igbavboa, and W.E. Muller Statins and neuroprotection: a prescription to move the field forward Ann N Y Acad Sci 1199 2010 69 76
76. N.E. Shepardson, G.M. Shankar, and D.J. Selkoe Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations Arch Neurol 68 2011 1385 1392
77. W. Jacobsen, B. Kuhn, and A. Soldner et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin Drug Metab Dispos 28 2000 1369 1378
78. L.N. Johnson-Anuna, G.P. Eckert, and J.H. Keller et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex J Pharmacol Exp Ther 312 2005 786 793
79. K.M. Thelen, K.M. Rentsch, and U. Gutteck et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin J Pharmacol Exp Ther 316 2006 1146 1152
80. A. Tsuji, A. Saheki, I. Tamai, and T. Terasaki Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier J Pharmacol Exp Ther 267 1993 1085 1090
81. A. Saheki, T. Terasaki, I. Tamai, and A. Tsuji In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors Pharm Res 11 1994 305 311
82. K. Nezasa, K. Higaki, and T. Matsumura et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin Drug Metab Dispos 30 2002 1158 1163
83. M. Schachter Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update Fundam Clin Pharmacol 19 2005 117 125
84. G. Guyatt Evidence-Based Medicine Working Group Users' guides to the medical literature: a manual for evidence-based clinical practice 2nd ed. 2008 McGraw-Hill Medical New York